Clinical Trial Update: A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AMY-101, a C3 inhibitor, in patients with ARDS due to severe COVID-19 (SARS-CoV-2 infection).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• AMY-101 (AMY-101)

Snippet

Sponsor: Amyndas Pharmaceuticals S.A. | Conditions: Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19) | Phase 2 | Status: UNKNOWN